Atezolizumab Suppliers & Bulk Manufacturers
Available Forms: Intravenous infusion
Available Strengths: 1200 mg/20 mL
Reference Brands: Tecentriq® (EU & US)
Category:
Oncology Cancer Care
Atezolizumab (Tecentriq®) is a PD-L1 checkpoint inhibitor used in urothelial carcinoma, NSCLC, and triple-negative breast cancer. Available as sterile IV infusion vials (1200 mg/20 mL), manufactured under EU-GMP and USFDA standards. Ideal for B2B supply, hospital tenders, and licensing.
Product Description:
Atezolizumab (Tecentriq®) is a PD-L1 immune checkpoint inhibitor indicated for urothelial carcinoma, NSCLC, and triple-negative breast cancer. Provided as sterile intravenous infusion vials (1200 mg/20 mL), Atezolizumab is produced under EU-GMP and USFDA standards. Offered for B2B supply, contract manufacturing, and licensing, it supports hospital tenders and oncology distributors with full regulatory documentation. This monoclonal antibody restores anti-tumor immunity by blocking PD-L1, making it a vital immuno-oncology therapy in US and European cancer treatment portfolios.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing